Latest Biotech News

UCB agreed to acquire Neurona Therapeutics in a cash-and-milestones transaction valued at $1.15 billion to expand its epilepsy pipeline. The deal structure includes a $650 million upfront payment,...

Early data in lung cancer indicate KRAS-targeted therapies may be moving beyond the first wave of disappointing durability. The report describes a new iteration of KRAS drugs showing more promise...

Revolution Medicine reported standout Phase III results for daraxonrasib in metastatic pancreatic ductal adenocarcinoma, generating a sharp investor reaction. In RASolute 302 (NCT06625320), the...

New data presented at ESCMID Global 2026 in Munich indicate that antiretroviral therapy can substantially slow HIV-associated accelerated biological aging. Researchers reported that, among people...

Noscendo will test clinical value for cell-free DNA metagenomic sequencing in sepsis diagnosis through a new €7.5 million German trial. The OptiSep project will position Noscendo’s CE-IVDR-marked...

A multi-center randomized controlled trial presented at ESCMID Global 2026 reported that enhanced oral care can cut non-ventilator-associated hospital-acquired pneumonia risk by 60%. The study...

Obsidian Therapeutics announced a merger with Galera Therapeutics backed by a $350 million infusion to support cancer drug trials. The combined company structure includes a public listing and a...

The Breakthrough Prize Foundation awarded the 2026 Life Sciences Breakthrough Prize to teams credited with pioneering gene therapy for distinct genetic diseases. The recognition highlighted work...

10x Genomics unveiled its Atera spatial platform at AACR, positioning it for whole-transcriptome spatial biology at scale. The company said the instrument is intended to address limitations in...

Odyssey Therapeutics has filed for a second attempt at an initial public offering after pulling its first effort a year earlier. The Boston-based biotech submitted its updated IPO paperwork as it...

A new round of KRAS-targeted therapies is showing early signs of stronger performance in lung cancer, according to early cuts of data reported in the latest coverage. The report frames this as a...

Obsidian Therapeutics and Galera Therapeutics announced a merger structure backed by a $350 million infusion aimed at advancing their combined tumor-infiltrating lymphocyte (TIL) cell therapy...

UCB disclosed plans to acquire clinical-stage epilepsy developer Neurona Therapeutics for $650 million, with potential milestone payments up to $500 million. The move is intended to broaden UCB’s...

Revolution Medicine reported striking Phase III outcomes for its once-daily oral KRAS-pathway candidate daraxonrasib (RASolute 302) in metastatic pancreatic ductal adenocarcinoma after prior...

Noscendo is pursuing clinical actionability and cost evidence for its cfDNA metagenomic sequencing platform in sepsis through a new €7.5 million German project. The effort, called OptiSep, will...

10x Genomics unveiled its Atera spatial instrument at AACR 2026, positioning the platform as whole-transcriptome spatial biology at scale. The company says Atera addresses trade-offs seen with...

Breakthrough Prize Foundation awarded the Life Sciences prize to teams credited with pioneering gene therapies for two genetic disease areas. The coverage highlights Jean Bennett, Albert Maguire,...

Breakthrough Prize recognition also extended to work identifying a shared genetic cause of ALS and FTD. The coverage credits Rosa Rademakers and Bryan Traynor with identifying the most common...

Researchers reported that wastewater surveillance can detect the emergence of drug-resistant Candida auris strains in healthcare settings, using wastewater-based epidemiology. The findings were...

Odyssey Therapeutics is attempting an IPO again after pulling its first attempt earlier, according to coverage that says the company submitted a second registration. The update signals continued...